LACTOLOGY FOUNDATION

Epomediol (ATC class A05BA05) is a synthetic terpenoid classified as a liver therapy agent with choleretic and antipruritic effects, mainly used for symptomatic treatment of pruritus associated with intrahepatic cholestasis, including cholestasis of pregnancy. Toxicological and lactational data are extremely scarce; current evidence does not support routine use during breastfeeding, and a precautionary approach is warranted.medpedia.framar+5

ATC and pharmacological class

Epomediol belongs to ATC code A05 “Bile and liver therapy,” subgroup A05B “Liver therapy, lipotropics,” and more specifically A05BA “Liver therapy,” where A05BA05 is assigned to epomediol as a distinct liver-therapy agent. Within this subgroup, epomediol is grouped with other hepatoprotective or hepatotropic medicines such as arginine glutamate, silymarin, citiolone, ornithine oxoglutarate, tidiacic arginine, and glycyrrhizic acid.wikipedia+2

Active substance and mechanism

Epomediol (trade name Clesidren) is described as a synthetic terpenoid, structurally related to terpenoid compounds with cholagogue and choleretic activity. Its primary pharmacodynamic effect is promotion of bile flow (choleresis), which may reduce pruritus and discomfort related to intrahepatic cholestasis; detailed molecular mechanisms (e.g. receptor-level actions) are not well characterized in publicly available sources.ebi+3

Therapeutic indications

The main documented indication for epomediol is symptomatic treatment of itching (pruritus) arising from intrahepatic cholestasis, particularly cholestasis of pregnancy. In national and ATC registries, it is classified more broadly as a drug for liver therapy, potentially used in clinical contexts where improving bile flow and liver function markers is desirable, although specific approved indications may vary by jurisdiction.wikipedia+7

Dosage and administration (general)

Publicly accessible data provide only limited information on epomediol dosing; individual national formularies and product characteristics should be consulted for exact dose ranges, treatment duration, and route of administration (commonly oral). Given its use in cholestatic pruritus, dosing is typically tailored to the severity of symptoms, the underlying hepatic condition, and patient-specific factors such as pregnancy status and concomitant medications.wikidoc+3

Contraindications

The Framar Medpedia entry explicitly lists hypersensitivity to epomediol or to any excipient as a contraindication. As with other hepatotropic medicines, additional practical contraindications may include significant acute hepatic failure, severe biliary obstruction, or conditions where increasing bile flow is clinically undesirable, although such details are not consistently specified in publicly available summaries and should be checked in official product information.adc+3

Adverse effects and toxicity

Systematically compiled adverse-effect data for epomediol are sparse; common hepatotropic-drug safety considerations (e.g. monitoring liver enzymes, gastrointestinal tolerance) should be applied, even though specific reaction profiles (such as frequency of diarrhea, abdominal pain, or elevated transaminases) are not well documented in open sources. In toxicological terms, the lack of robust human and animal data requires a conservative risk assessment, emphasizing vigilant clinical monitoring and prompt discontinuation in the event of liver-function deterioration, hypersensitivity, or unexpected systemic effects.drugbank+4

Special populations: pregnancy

Epomediol has been used specifically in intrahepatic cholestasis of pregnancy to alleviate maternal pruritus, and this clinical context appears repeatedly in available references. Nevertheless, formal reproductive-toxicity evaluations and controlled studies in pregnant women are not readily accessible; epomediol should therefore be reserved for situations where potential symptomatic benefit outweighs theoretical fetal risks, under specialist supervision and in line with national regulatory guidance.medpedia.framar+5

Special populations: lactation

No dedicated pharmacokinetic, milk-transfer, or infant-outcome data for epomediol in breastfeeding women have been identified in current open sources. Given its synthetic terpenoid nature and hepatic-biliary action, and in the absence of specific lactation safety evidence, epomediol should be considered a drug with unknown safety in breastfeeding, and its use is generally discouraged unless clearly necessary and safer alternatives are unavailable.aboutkidshealth+5

Toxicological–lactational risk assessment

From a toxicological–lactological perspective, epomediol cannot be classified as compatible with breastfeeding on an evidence base comparable to commonly used postpartum medications, because published data are virtually absent. Applying general principles of medication use in lactation—where most medicines with limited systemic toxicity and short half-lives are safe, but drugs lacking data require caution—epomediol should be assigned a precautionary risk category (e.g. “avoid during breastfeeding or use only with specialist justification and close monitoring of the infant and maternal liver function”).wikipedia+5

Monitoring and clinical precautions

When epomediol is used, baseline and periodic assessment of liver function tests (transaminases, bilirubin, alkaline phosphatase, gamma‑GT) is advisable to detect hepatotoxicity or unexpected changes in cholestasis. In lactating or postpartum patients, careful documentation of maternal symptoms, infant feeding behavior, weight gain, and any signs of sedation or gastrointestinal disturbance is prudent, with immediate discontinuation of the drug and medical review if adverse effects are suspected.drugbank+4

Web-page style monograph structure

Below is the content structured as a web-page style monograph suitable for your database (English language, concise sections, and headings).

Epomediol (ATC A05BA05) – Toxicological–Lactological Monograph

Name and classification

·        International name: Epomediol (Clesidren).

·        ATC code: A05BA05 – Liver therapy.atccode+2

·        Pharmacological group: Liver therapy, hepatotropic choleretic agent.wikipedia+3

Pharmacology and mechanism

Epomediol is a synthetic terpenoid with choleretic properties, promoting bile flow from the liver and biliary tract. The exact molecular mechanism has not been fully elucidated; its clinical effect is presumed to arise from improved bile excretion and reduction of cholestasis-related pruritus.ebi+3

Clinical indications

Epomediol is indicated for symptomatic treatment of pruritus associated with intrahepatic cholestasis, including cholestasis of pregnancy. It is classified as a drug for bile and liver therapy and may be used as part of supportive management of chronic liver disorders where cholestasis contributes to symptoms.wikidoc+6

Contraindications

·        Known hypersensitivity to epomediol or to any excipient in the medicinal product.medpedia.framar

·        Use is generally contraindicated or requires caution in patients with severe acute hepatic failure, complete biliary obstruction, or other conditions where increased bile flow is clinically inappropriate, as inferred from general principles of liver therapy.adc+3

Adverse reactions and toxicity

Published safety data for epomediol are limited; a detailed adverse‑reaction profile is not available in open-access references. Potential adverse events may include gastrointestinal discomfort, changes in liver enzymes, and hypersensitivity reactions, and clinical monitoring is recommended during treatment.drugbank+4

Use in pregnancy

Epomediol has been used to relieve pruritus in intrahepatic cholestasis of pregnancy and is mentioned in this context in multiple references. However, controlled data on fetal safety, teratogenicity, or pregnancy outcomes are lacking; prescribing should be restricted to specialist care when expected benefit outweighs potential risks.wikipedia+5

Use during lactation

There are no specific pharmacokinetic or clinical studies evaluating epomediol in breastfeeding women. Because milk transfer, infant exposure, and long‑term neurodevelopmental outcomes are unknown, epomediol should be considered a drug of uncertain safety during breastfeeding, and alternative treatments with established lactation profiles are preferred.aboutkidshealth+5

Toxicological–lactological safety summary

·        Evidence base: Very limited; no dedicated lactation or neonatal data.

·        Maternal toxicity: Requires monitoring of liver function and overall clinical status.drugbank+3

·        Lactational recommendation: Avoid use during breastfeeding whenever possible; if therapy is deemed essential, apply shortest effective course, schedule dosing after feeds when feasible, and closely observe the infant, documenting in a risk–benefit framework.aboutkidshealth+3